Results 71 to 80 of about 17,302 (216)

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium

open access: yesBritish Journal of Haematology, EarlyView.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas   +22 more
wiley   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

open access: yesBritish Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne   +28 more
wiley   +1 more source

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

open access: yesFrontiers in Pharmacology
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Zhaorui Wang   +5 more
doaj   +1 more source

Intravesical Instillation of Azacitidine Suppresses Tumor Formation through TNF-R1 and TRAIL-R2 Signaling in Genotoxic Carcinogen-Induced Bladder Cancer

open access: yes, 2021
Azacitidine, an inhibitor of DNA methylation, shows therapeutic effects against several malignancies by inducing apoptosis and inhibiting tumor cell proliferation.
Ya-Chuan Chang   +5 more
core   +1 more source

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper   +27 more
wiley   +1 more source

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

open access: yesHaematologica
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism.
Guru Subramanian Guru Murthy   +17 more
doaj   +1 more source

Combined azacitidine and romidepsin enhances cytotoxicity in azacitidine-sensitive but not in azacitidine-resistant multiple myeloma cell lines. [PDF]

open access: yes
In hematopoietic tumor cells, aberrant epigenetic alterations of hypermethylation or histone deacetylation are usually observed. In multiple myeloma (MM), histone deacetylase inhibitors (HDIs) have proven anti-tumor activity, whereas the effects of DNA ...
Ozawa, Keiya   +2 more
core  

The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary The leukaemia in pregnancy study was a multicentre retrospective study of pregnancy outcomes of women with concurrent (CAL) or previous (PAL) acute leukaemia. Cases were identified from eight hospitals. Of 39 screened cases, 12 CAL and 21 PAL cases were described, with one belonging to both groups.
Lukas Pitel   +14 more
wiley   +1 more source

Demethylating Agents in the Treatment of Cancer

open access: yesPharmaceuticals, 2010
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies.
Paul M. Howell, Jr.   +2 more
doaj   +1 more source

Ligand atom energies and contribution of the iNOS residues/molecules with azacitidine.

open access: yes, 2023
Ligand atom energies and contribution of the iNOS residues/molecules with azacitidine.
Mahdieh Lashkarizadeh (16955395)   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy